Showing 2 posts of 2 posts found.
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
Care Quality Commission appoints Emily Miles as Chief Executive
National survey aims to improve glaucoma care across the UK
Phase 3 trials support expanded use of Dysport for migraine prevention
Roche secures CE Mark for automated latent tuberculosis blood test
ReproNovo Phase 2 fertility study doses first participant